- Home
- BPOP vs GKOS Comparison
BPOP vs GKOS Comparison
Compare BPOP & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BPOP | GKOS |
|---|---|---|
| Founded | 1893 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 6.9B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | BPOP | GKOS |
|---|---|---|
| Price | $140.22 | $119.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 14 |
| Target Price | ★ $147.70 | $133.07 |
| AVG Volume (30 Days) | 595.1K | ★ 763.3K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | $14.80 | $23.29 |
| Revenue Next Year | $5.54 | $27.74 |
| P/E Ratio | $11.87 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $78.23 | $73.16 |
| 52 Week High | $149.31 | $130.23 |
Technical Indicators
Market Signals| Indicator | BPOP | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 55.05 | 58.23 |
| Support Level | $140.00 | $78.93 |
| Resistance Level | $149.31 | $130.23 |
| Average True Range (ATR) | 4.14 | 5.29 |
| MACD | -0.66 | 0.83 |
| Stochastic Oscillator | 15.95 | 99.89 |
Price Performance
Historical ComparisonAbout BPOP Popular Inc.
Popular Inc, based in Puerto Rico, is a financial holding company with four main subsidiaries: Banco Popular de Puerto Rico, a bank in Puerto Rico in terms of assets; Banco Popular North America, its banking operation in the continental United States; Evertec, a data processor; and Popular Financial Holdings, a diversified financial services company. The Corporation's reportable segments consist of Banco Popular de Puerto Rico and Popular U.S.
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.